{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:16:30Z","timestamp":1793776590312,"version":"4.6.1"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Agentschap voor Innovatie door Wetenschap en Technologie (IWT), Flanders, Belgium","id":[{"id":"https:\/\/ror.org\/01antkr91","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,2,11]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We previously reported that dendritic cell-based mRNA vaccination plus ipilimumab (TriMixDC-MEL IPI) results in an encouraging rate of tumor responses in patients with pretreated advanced melanoma. Here, we report the TriMixDC-MEL IPI-induced T-cell responses detected in the peripheral blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix) as well as the tumor-associated antigens tyrosinase, gp100, MAGE-A3, or MAGE-C2 were administered together with IPI for four cycles. For 18\/39 patients, an additional vaccine was administered before the first IPI administration. We evaluated tumor-associated antigen specific T-cell responses in previously collected peripheral blood mononuclear cells, available from 15 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Vaccine-induced enzyme-linked immunospot assay responses detected after in vitro T-cell stimulation were shown in 12\/15 patients. Immune responses detected in patients with a complete or partial response were significantly stronger and broader, and exhibited a higher degree of multifunctionality compared with responses in patients with stable or progressive disease. CD8+ T-cell responses from patients with an ongoing clinical response, either elicited by TriMixDC-MEL IPI or on subsequent pembrolizumab treatment, exhibited the highest degree of multifunctionality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TriMixDC-MEL IPI treatment results in robust CD8+ T-cell responses in a meaningful portion of stage III or IV melanoma patients, and obviously in patients with a clinical response. The levels of polyfunctional and multiantigen T-cell responses measured in patients with a complete response, particularly in patients evidently cured after 5+ years of follow-up, may provide a benchmark for the level of immune stimulation needed to achieve a durable clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01302496\">NCT01302496<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2019-000329","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T04:35:22Z","timestamp":1582950922000},"page":"e000329","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":155,"title":["TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01302496","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-1968","authenticated-orcid":false,"given":"Brenda","family":"De Keersmaecker","sequence":"first","affiliation":[{"name":"eTheRNA immunotherapies, Niel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Claerhout","sequence":"additional","affiliation":[{"name":"eTheRNA immunotherapies, Niel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Carrasco","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Oncology, Institute of Pathology and Genetics, Grand Hopital de Charleroi, Charleroi, Hainaut, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bar","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Oncology, Institute of Pathology and Genetics, Grand Hopital de Charleroi, Charleroi, Hainaut, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Corthals","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Wilgenhof","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Thielemans","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussel, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"2025100314325975000_8.1.e000329.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2025100314325975000_8.1.e000329.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025100314325975000_8.1.e000329.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.10.001"},{"key":"2025100314325975000_8.1.e000329.4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.cell.2018.11.048","article-title":"NKG2A, a new kid on the immune checkpoint block","volume":"175","author":"Haanen","year":"2018","journal-title":"Cell"},{"key":"2025100314325975000_8.1.e000329.5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100314325975000_8.1.e000329.6","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.77"},{"key":"2025100314325975000_8.1.e000329.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt245"},{"key":"2025100314325975000_8.1.e000329.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4121"},{"key":"2025100314325975000_8.1.e000329.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2010.07.003"},{"key":"2025100314325975000_8.1.e000329.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018801","article-title":"Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis","volume":"6","author":"Draube","year":"2011","journal-title":"PLoS One"},{"key":"2025100314325975000_8.1.e000329.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100314325975000_8.1.e000329.12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100314325975000_8.1.e000329.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1254"},{"key":"2025100314325975000_8.1.e000329.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa3828"},{"key":"2025100314325975000_8.1.e000329.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3496"},{"key":"2025100314325975000_8.1.e000329.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100314325975000_8.1.e000329.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2025100314325975000_8.1.e000329.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00394","article-title":"Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer","volume":"9","author":"Versteven","year":"2018","journal-title":"Front Immunol"},{"key":"2025100314325975000_8.1.e000329.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3"},{"key":"2025100314325975000_8.1.e000329.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.12.010"},{"key":"2025100314325975000_8.1.e000329.21","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.11"},{"key":"2025100314325975000_8.1.e000329.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0104"},{"key":"2025100314325975000_8.1.e000329.23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1600-6143.2003.00293.x"},{"key":"2025100314325975000_8.1.e000329.24","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12170"},{"key":"2025100314325975000_8.1.e000329.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0402"},{"key":"2025100314325975000_8.1.e000329.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.5675"},{"key":"2025100314325975000_8.1.e000329.27","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/569751"},{"key":"2025100314325975000_8.1.e000329.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503726102"},{"key":"2025100314325975000_8.1.e000329.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0503"},{"key":"2025100314325975000_8.1.e000329.30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008918"},{"key":"2025100314325975000_8.1.e000329.31","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-6-22","article-title":"Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma","volume":"6","author":"Comin-Anduix","year":"2008","journal-title":"J Transl Med"},{"key":"2025100314325975000_8.1.e000329.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810114105"},{"key":"2025100314325975000_8.1.e000329.33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0068"},{"key":"2025100314325975000_8.1.e000329.34","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:33:09Z","timestamp":1759527189000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,28]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/jitc-2019-000329"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000329","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}